Your browser doesn't support javascript.
loading
An assessment of the strategy and status of COVID-19 vaccination in India.
Gupta, Sneh Lata; Goswami, Surbhi; Anand, Ananya; Naman, Namrata; Kumari, Priya; Sharma, Priyanka; Jaiswal, Rishi K.
Afiliação
  • Gupta SL; National Institute of Immunology, New Delhi, 110067, India.
  • Goswami S; National Institute of Immunology, New Delhi, 110067, India.
  • Anand A; Department of Zoology, Patna Science College, Patna University, Bihar, India.
  • Naman N; Department of Zoology, Patna Science College, Patna University, Bihar, India.
  • Kumari P; Department of Zoology, Patna Science College, Patna University, Bihar, India.
  • Sharma P; Department of Zoology, Patna Science College, Patna University, Bihar, India.
  • Jaiswal RK; Department of Cancer Biology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 60153, USA. rishijai24@gmail.com.
Immunol Res ; 71(4): 565-577, 2023 08.
Article em En | MEDLINE | ID: mdl-37041424
ABSTRACT
The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Immunol Res Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Immunol Res Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia